MS Treatments

The below disease modifying treatments (DMT’s) are available for the treatment of MS in New Zealand.

 

First line treatments for Relapsing Remitting MS (funded)

Gilenya® (Fingolimod)

Aubagio® (teriflunomide)

Tecfidera® (Dimethyl fumarate)

Tysabri® (Natalizumab)

 

Second line treatments for Relapsing Remitting MS (funded)

Copaxone® (glatiramer acetate)

Interferons

 

Disease Modifying Treatment Special Authority Criteria

Information on the entry and exit criteria for the PHARMAC funded treatments and application process.

 

Other disease modifying treatments (DMTs) and symptom management medications (available in NZ but not-funded)

Sativex® Nabiximols (NEW)

Fampyra® (fampridine)

LDN-Low-Dose Naltrexone (LDN)

Steroids

 

Disease modifying treatments (DMTs) not currently available in NZ

Ocrevus® (Ocrelizumab(NEW)

Stem Cell Treatment (NEW)

 

MORE ABOUT MS

Stem Cell Transplant
Managing and Treating MS

Stem cell therapy is any treatment that uses or targets stem cells

arrow
Clinical Trials
What are they?

Information to help you decide

arrow
Research
Research and Studies

News and updates

arrow